Children's Health Defense To have a truly robust vaccine it must afford long-lasting immunity. It is with this category that the COVID-19 countermeasures fall well short of any definition that can be equated to robust.
By Daniel O’Connor
According to a Science Translational Medicine paper, mRNA vaccines targeting COVID-19 elicit robust antibody responses in the circulation, which support protection from morbidity and mortality.
The commentary fails to highlight the significant limitations of the mRNA-based countermeasures, a two-prong problem of durability and a mutating viral pathogen, meaning by month three or four the benchmark of protection, a surge in antibodies, wanes substantially.
The authors of the paper wanted to better understand mRNA vaccine mucosal response, and specifically, the extent to which mRNA vaccines, which are delivered intramuscularly, would bolster mucosal immune protection.
Enter this Science Translational Medicine assessment. Reviewing two bodies of research documented and published by Declercq et al. and Lasrado et al., involved the use of human nasal swab samples in both studies.
…
Read Full Article Here…(childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
Live Stream + Chat (zutalk.com)
